Venture Capital Investors

Addex Therapeutics

Addex Therapeutics is a VC investing group that backs high-potential tech companies.

Venture Investor Overview

Contact Information

Background Information

Overview

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex also holds a 20% equity interest in a private company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders.

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

6/30/2025

Transaction History

Our records indicate that Addex Therapeutics invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Investor Contacts

Title

Name

Email & Social

Chief Executive Officer

Tim Dyer

        

Funds

No fund closings have been recorded for this company.

Portfolio Companies

Addex Therapeutics has invested in only one tech company, according to our database records. If we are missing a portfolio company, please let us know.

Browse more venture capital investors:

Add Partners | Additio Investment

Share this article

About Our VC Investors Database

This venture capital firm data comes via a partnership with VentureDeal.com, a market leader in private equity transaction data.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary